Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Lignende værker

• Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
  af: Hey, John A., et al.
  Udgivet: (2018)
• Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
  af: Hey, John A., et al.
  Udgivet: (2018)
• Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
  af: Hey, John A., et al.
  Udgivet: (2017)
• Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
  af: Cummings, Jeffrey, et al.
  Udgivet: (2021)
• APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
  af: Abushakra, Susan, et al.
  Udgivet: (2020)